Qiang Wang - Alibaba Health Executive Director
| TWY Stock | EUR 0.35 0.01 2.78% |
Director
Mr. Wang Qiang is an Executive Director of the Company. He joined the Group as chief financial officer since September 2017, and is responsible for the Groups financial management, capital markets, internal controls and procurement. He currently serves as a director of certain subsidiaries of the Company and also acts as a consultant to Alibaba Group Holding Limited and its subsidiaries. Prior to joining the Group, Mr. Wang was the vice president of Intime Retail Company Limited since January 2014 and chief financial officer of Intime since July 2014, and was responsible for the companys financial management, cost control, investment development, legal affairs, information management, capital markets and investor relations. He had been assistant to president of Intime since February 2012 and general manager of financial management department of Intime since March 2008, responsible for Intimes financial management. Prior to joining Intime, he took various financial management positions in Veolia Water, Asia Pacific and ABB China from 1999 to 2008 since 2018.
| Age | 40 |
| Tenure | 6 years |
| Phone | 852 2583 9333 |
| Web | https://www.alihealth.cn |
Alibaba Health Management Efficiency
The company has return on total asset (ROA) of (0.0168) % which means that it has lost $0.0168 on every $100 spent on assets. This is way below average. Alibaba Health's management efficiency ratios could be used to measure how well Alibaba Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Richard Bradeen | Superior Plus Corp | 61 | |
| Robert Engbloom | Superior Plus Corp | 64 | |
| Frank Hermance | Sugi Holdings CoLtd | 68 | |
| Daniel Cronin | Intel | N/A | |
| Walentin Mirosh | Superior Plus Corp | 71 | |
| Alan Harris | Sugi Holdings CoLtd | 64 | |
| Patrick Gottschalk | Superior Plus Corp | 54 | |
| Anne Pol | Sugi Holdings CoLtd | 70 | |
| David Smith | Superior Plus Corp | 59 | |
| Marvin Schlanger | Sugi Holdings CoLtd | 69 | |
| Eugene Bissell | Superior Plus Corp | 64 | |
| Randall Findlay | Superior Plus Corp | 67 | |
| Roger Vincent | Sugi Holdings CoLtd | 70 | |
| Richard Gochnauer | Sugi Holdings CoLtd | 68 | |
| Ernest Jones | Sugi Holdings CoLtd | 69 | |
| William Ruthrauff | Sugi Holdings CoLtd | N/A | |
| Catherine Best | Superior Plus Corp | 64 | |
| Theodore Dosch | Sugi Holdings CoLtd | 58 | |
| Shawn Puccio | Sugi Holdings CoLtd | 51 | |
| James Stallings | Sugi Holdings CoLtd | 62 | |
| Douglas Harrison | Superior Plus Corp | 58 | |
Management Performance
| Return On Equity | 0.0088 | |||
| Return On Asset | -0.0168 |
Alibaba Health Infor Leadership Team
Elected by the shareholders, the Alibaba Health's board of directors comprises two types of representatives: Alibaba Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alibaba. The board's role is to monitor Alibaba Health's management team and ensure that shareholders' interests are well served. Alibaba Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alibaba Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yanwu Tu, CFO Director | ||
| Aishan Lew, Company Secretary | ||
| Yi Huang, Non-Executive Independent Director | ||
| Xiao Chen, Executive Vice Chairman of the Board | ||
| Aizhu Huang, Non-Executive Director | ||
| Shunyan Zhu, Chairman CEO | ||
| Yu Zhang, Non-Executive Director | ||
| Chun Kwong, Financial Controller | ||
| Kin Au, Company Secretary | ||
| Xuan Yan, Non-Executive Independent Director | ||
| Lei Wang, CEO, Executive Director | ||
| Chung Tsai, Non-Executive Director | ||
| Ka Chun, Company Sec | ||
| Hong Xu, Non-Executive Director | ||
| Yongming Wu, Non-Executive Chairman of the Board | ||
| Difan Shen, CEO, Executive Director | ||
| Kai Kang, Non-Executive Director | ||
| Tong Luo, Non-Executive Independent Director | ||
| Qiang Wang, Executive Director | ||
| On King, Non-Executive Independent Director | ||
| Chun Yan, Company Sec |
Alibaba Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alibaba Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0088 | |||
| Return On Asset | -0.0168 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | (0.02) % | |||
| Current Valuation | 14.05 B | |||
| Shares Outstanding | 13.52 B | |||
| Shares Owned By Insiders | 64.61 % | |||
| Shares Owned By Institutions | 11.01 % | |||
| Price To Book | 7.98 X | |||
| Price To Sales | 0.56 X |
Currently Active Assets on Macroaxis
| LAAC | Lithium Americas Corp | |
| F | Ford Motor | |
| CHPT | ChargePoint Holdings | |
| AXL | American Axle Manufacturing | |
| ICLN | iShares Global Clean |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alibaba Health Information. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Alibaba Stock analysis
When running Alibaba Health's price analysis, check to measure Alibaba Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alibaba Health is operating at the current time. Most of Alibaba Health's value examination focuses on studying past and present price action to predict the probability of Alibaba Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alibaba Health's price. Additionally, you may evaluate how the addition of Alibaba Health to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |